ENVOYA Trademark
Trademark Overview
On Thursday, January 25, 2024, a trademark application was filed for ENVOYA with the United States Patent and Trademark Office. The USPTO has given the ENVOYA trademark a serial number of 98376231. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, October 28, 2024. This trademark is owned by Envoya Inc.. The ENVOYA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Gene therapy products, namely, non-lipid polymer based nanoparticles for gene therapy; gene therapy products, namely polymer-based nanoparticles for medical, veterinary and pharmaceutical purposes; nucleic acid-containing products, namely RNA and DNA, for medical or veterinary purposes; gene therapy products for the treatment of cancer, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, or inflammatory diseases or disorders, namely, non viral vectors; nanoparticle products for medical or veterinary purposes, namely, non lipid polymer based nanoparticles; microparticle products for medical or veterinary purposes, namely, non lipid polymer based microparticles; nanoparticles for medical or veterinary purposes, namely, non lipid polymer based nanoparticles; microparticles for medical or veterinary purposes, namely, non lipid polymer based microparticles that facilitate the delivery of pharmaceutical preparat...
Pharmaceutical research and development; research and development services in the field of pharmaceuticals; gene therapy research and development services; research and development services relating to the delivery of RNA and DNA therapeutics to patients; research and development services in the field of nanoparticles and microparticles; research and development services in the field of nucleic acid-containing particles; research and development services in the field of nucleic acids, proteins, and small molecules delivery; Development of nucleic acids, namely RNA and DNA, for encapsulating nanoparticles for targeted delivery; Research services in the field of nanoparticle characteristics; Research services in the field of microparticle characteristics; research and development services in the field of pharmaceutical preparations for the treatment of disease or disorders; research and development services in the field of pharmaceutical preparations for the treatment of cancer, muscular...
General Information
| Serial Number | 98376231 |
| Word Mark | ENVOYA |
| Filing Date | Thursday, January 25, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, October 28, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 31, 2024 |
Trademark Statements
| Goods and Services | Gene therapy products, namely, non-lipid polymer based nanoparticles for gene therapy; gene therapy products, namely polymer-based nanoparticles for medical, veterinary and pharmaceutical purposes; nucleic acid-containing products, namely RNA and DNA, for medical or veterinary purposes; gene therapy products for the treatment of cancer, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, or inflammatory diseases or disorders, namely, non viral vectors; nanoparticle products for medical or veterinary purposes, namely, non lipid polymer based nanoparticles; microparticle products for medical or veterinary purposes, namely, non lipid polymer based microparticles; nanoparticles for medical or veterinary purposes, namely, non lipid polymer based nanoparticles; microparticles for medical or veterinary purposes, namely, non lipid polymer based microparticles that facilitate the delivery of pharmaceutical preparations; nanoparticles that encapsulate a nucleic acid payload for delivery to a cell or tissue for medical or veterinary purposes; microparticles that encapsulate a nucleic acid payload for delivery to a cell or tissue for medical or veterinary purposes; nanoparticles that encapsulate nucleic acids, proteins, small molecules for medical or veterinary purposes; microparticles that encapsulate nucleic acids, proteins, small molecules for medical or veterinary purposes; nanoparticles that encapsulate nucleic acids for medical or veterinary purposes; nanoparticles that encapsulate cytotoxic payloads in cells for medical or veterinary purposes; microparticles that encapsulate cytotoxic payloads in cells for medical or veterinary purposes; diagnostic preparations and chemical and diagnostic reagents for clinical or medical laboratory use |
| Translation of Words in Mark | The English translation of "ENVOYA" in the mark is "SEND". |
| Goods and Services | Pharmaceutical research and development; research and development services in the field of pharmaceuticals; gene therapy research and development services; research and development services relating to the delivery of RNA and DNA therapeutics to patients; research and development services in the field of nanoparticles and microparticles; research and development services in the field of nucleic acid-containing particles; research and development services in the field of nucleic acids, proteins, and small molecules delivery; Development of nucleic acids, namely RNA and DNA, for encapsulating nanoparticles for targeted delivery; Research services in the field of nanoparticle characteristics; Research services in the field of microparticle characteristics; research and development services in the field of pharmaceutical preparations for the treatment of disease or disorders; research and development services in the field of pharmaceutical preparations for the treatment of cancer, muscular dystrophy, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, inflammatory diseases or disorders, rare diseases; scientific and technological services, namely, scientific research, analysis, optimization testing, development of protocols in the field of nucleic acids, proteins, and small molecules delivery to human cells; scientific and technological services, namely, scientific research, analysis, optimization testing, development of protocols in the field of protein delivery to human cells; Scientific and technological services, namely, research and design relating to scientific and technological services in the field of nucleic acids, proteins, and small molecules therapeutics |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 25, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 25, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Envoya Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Brookline, MA 02445 |
Trademark Events
| Event Date | Event Description |
| Thursday, January 25, 2024 | NEW APPLICATION ENTERED |
| Thursday, July 25, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, August 28, 2024 | NON-FINAL ACTION E-MAILED |
| Thursday, October 17, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, October 17, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, October 22, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 21, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, August 28, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, August 28, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, October 17, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
